# Hyperfine, Inc.: overview HYPR · Nasdaq · CIK 1833769 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/hypr.md) · [Financials](/companies/hypr/financials.md) · [Filings](/companies/hypr/filings.md) · [Insiders](/companies/hypr/insiders.md) Latest reported revenue: [$3.9m](/filings/0001193125-26-338015.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-338015). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [3,643](/filings/0001193125-25-280212.md) | [2,321 d](/filings/0001193125-26-114044.md) | [2,137](/filings/0001193125-26-219428.md) | [2,696](/filings/0001193125-26-338015.md) | [3,437](/filings/0001193125-25-280212.md) | [5,293 d](/filings/0001193125-26-114044.md) | [3,903](/filings/0001193125-26-219428.md) | [3,904](/filings/0001193125-26-338015.md) | | Gross margin | % | [52.4%](/filings/0001193125-25-280212.md) | [35.6% d](/filings/0001193125-26-114044.md) | [41.3%](/filings/0001193125-26-219428.md) | [49.3%](/filings/0001193125-26-338015.md) | [53.8%](/filings/0001193125-25-280212.md) | [50.9% d](/filings/0001193125-26-114044.md) | [50.7%](/filings/0001193125-26-219428.md) | [50.7%](/filings/0001193125-26-338015.md) | | Operating margin | % | [(300.9%)](/filings/0001193125-25-280212.md) | [(463.8%) d](/filings/0001193125-26-114044.md) | [(510.2%)](/filings/0001193125-26-219428.md) | [(355.9%)](/filings/0001193125-26-338015.md) | [(259.5%)](/filings/0001193125-25-280212.md) | [(144.9%) d](/filings/0001193125-26-114044.md) | [(219.3%)](/filings/0001193125-26-219428.md) | [(216.9%)](/filings/0001193125-26-338015.md) | | Net margin | % | [(283.4%)](/filings/0001193125-25-280212.md) | [(447.7%) d](/filings/0001193125-26-114044.md) | [(440.7%)](/filings/0001193125-26-338015.md) | [(342.2%)](/filings/0001193125-26-338015.md) | [(320.6%)](/filings/0001193125-25-280212.md) | [(111.7%) d](/filings/0001193125-26-114044.md) | [(220.9%)](/filings/0001193125-26-338015.md) | [(238.2%)](/filings/0001193125-26-338015.md) | | Diluted EPS | $ per share | [(0.14)](/filings/0001193125-25-280212.md) | not reported | [(0.12)](/filings/0001193125-26-219428.md) | [(0.12)](/filings/0001193125-26-338015.md) | [(0.14)](/filings/0001193125-25-280212.md) | not reported | [(0.09)](/filings/0001193125-26-219428.md) | [(0.09)](/filings/0001193125-26-338015.md) | | Free cash flow | $k | [(8,676) d](/filings/0001193125-25-280212.md) | [(8,365) d](/filings/0001193125-26-114044.md) | [(9,721)](/filings/0001193125-26-219428.md) | [(8,430) d](/filings/0001193125-26-338015.md) | [(5,712) d](/filings/0001193125-25-280212.md) | [(5,270) d](/filings/0001193125-26-114044.md) | [(9,250)](/filings/0001193125-26-219428.md) | [(7,298) d](/filings/0001193125-26-338015.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.5](/filings/0000950170-23-009159.md) | [6.8](/filings/0000950170-24-035343.md) | [11.0](/filings/0000950170-25-040281.md) | [12.9](/filings/0001193125-26-114044.md) | [13.6](/filings/0001193125-26-114044.md) | | Gross margin | % | [(78.0%)](/filings/0000950170-23-009159.md) | [13.3%](/filings/0000950170-24-035343.md) | [43.1%](/filings/0000950170-25-040281.md) | [45.7%](/filings/0001193125-26-114044.md) | [49.8%](/filings/0001193125-26-114044.md) | | Operating margin | % | [(4336.1%)](/filings/0000950170-23-009159.md) | [(1084.2%)](/filings/0000950170-24-035343.md) | [(436.1%)](/filings/0000950170-25-040281.md) | [(335.3%)](/filings/0001193125-26-114044.md) | [(273.4%)](/filings/0001193125-26-114044.md) | | Net margin | % | [(4335.0%)](/filings/0000950170-23-009159.md) | [(649.2%)](/filings/0000950170-25-040281.md) | [(401.0%)](/filings/0000950170-25-040281.md) | [(315.9%)](/filings/0001193125-26-114044.md) | [(262.3%)](/filings/0001193125-26-114044.md) | | Diluted EPS | $ per share | [(17.57)](/filings/0000950170-23-009159.md) | [(1.04)](/filings/0000950170-24-035343.md) | [(0.62)](/filings/0000950170-25-040281.md) | [(0.56)](/filings/0001193125-26-114044.md) | [(0.43)](/filings/0001193125-26-114044.md) | | Free cash flow | $m | [(49.9)](/filings/0000950170-23-009159.md) | [(72.9)](/filings/0000950170-24-035343.md) | [(42.6)](/filings/0000950170-25-040281.md) | [(39.2)](/filings/0001193125-26-114044.md) | [(29.1)](/filings/0001193125-26-114044.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hypr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $6.3m | 4,673,087 | | Added +4,098,184 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.6m | 3,380,087 | | Reduced −73,076 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.6m | 1,960,811 | | Added +1,005,551 | | [Fosun International Ltd](/funds/1447884.md) | 2026-06-30 | $2.4m | 1,742,020 | | Unchanged | | [Catalio Capital Management, LP](/funds/1958125.md) | 2026-06-30 | $1.8m | 1,320,041 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.4m | 1,016,970 | | Added +692,900 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.3m | 945,836 | | Added +215,603 | | [Alphabet Inc.](/funds/1652044.md) | 2026-06-30 | $1.2m | 898,720 | | Unchanged | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $854.6k | 633,054 | | Added +455,686 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $765.6k | 567,109 | | Added +40,403 | ## Recent filings [All 366 filings](/companies/hypr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-08 | 11:40 ET | [8-K](/filings/0001193125-26-417437.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-417437 | | 2026-09-18 | 20:07 ET | [8-K](/filings/0001193125-26-395525.md) | 3.01 Delisting notice | 0001193125-26-395525 | | 2026-08-06 | 20:11 ET | [10-Q](/filings/0001193125-26-338015.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338015 | | 2026-08-06 | 20:05 ET | [8-K](/filings/0001193125-26-337963.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-337963 | | 2026-05-21 | 20:11 ET | [8-K](/filings/0001193125-26-234426.md) | 5.07 Shareholder vote results | 0001193125-26-234426 | | 2026-05-12 | 20:11 ET | [10-Q](/filings/0001193125-26-219428.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219428 | | 2026-05-12 | 20:06 ET | [8-K](/filings/0001193125-26-219380.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219380 | | 2026-04-08 | 20:10 ET | [DEF 14A](/filings/0001193125-26-147623.md) | Proxy statement, period 2026-05-21 | 0001193125-26-147623 | | 2026-03-18 | 20:21 ET | [10-K](/filings/0001193125-26-114044.md) | Annual report, period 2025-12-31 | 0001193125-26-114044 | | 2026-03-18 | 20:15 ET | [8-K](/filings/0001193125-26-113996.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-113996 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-114044.md), filed Mar 18, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1833769 - Tickers: HYPR - Exchange: Nasdaq - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.